The government, through the Pharmacy and Poisons Board (PPB), has issued an urgent alert over substandard batches of paracetamol 1000 mg/100 ml injections found in the Kenyan market and ordered their immediate recall.
In a statement signed by PPB Chief Executive Officer Dr Fred Siyoi on Thursday, April 24, 2025, the Board flagged several batches of Lumidol, Blink, and Paragen injections after they were found to have undergone a noticeable colour change, a potential sign of compromised quality.
The board further directed all pharmacies, healthcare providers, and members of the public to immediately cease the distribution, sale, or use of the affected batches and return them to the nearest health facility or supplier.
“The oard advises all pharmaceutical outlets, healthcare facilities, healthcare professionals, and members of the public to immediately cease further distribution, sale, issuing, or use of the outlined product batches and return the same to their nearest healthcare facility or respective suppliers, Dr Siyoi said.
According to Dr Siyoi, all the affected batches were manufactured by KamlaAmrut Pharmaceutical LLP, an India-based company.
“In execution of the foregoing mandate, the Board draws public attention to the detection of substandard batches of Paracetamol 1000 mg/100 1000 mg/100 1000 mg/100 1000 mg/100 1000 mg/100 ml Injection identified in the Kenyan market, which have exhibited a colour change,” Dr Siyoi said.
“Lumidol Injection: Batch Numbers CM4594007, CM4594008, and CM4594009, Manufactured by KamlaAmrut Pharmaceutical LLP, India. 2. Blink Injection: Batch Numbers CS4594005 and CS4594004, Manufactured by KamlaAmrut Pharmaceutical LLP, India. 3. Paragen injection: Batch Number K4290027, Manufactured by KamlaAmrut Pharmaceutical LLP, India.”
In addition, the board urged the public to report suspected substandard medicines or adverse drug reactions to the nearest health facility or directly to the Pharmacy and Poisons Board through its available reporting channels.
“The Board encourages the public to report any suspected cases of substandard medicines or adverse drug reactions to the nearest healthcare facility or the Pharmacy and Poisons Board through the following channels,” he added.
Furthermore, Dr Siyoi said that they will continue investigations and work closely with relevant agencies to ensure accountability and safeguard public health.
“The board is committed to ensuring the safety and efficacy of medicines in the market to protect public health,” he added.
You might also like
